Despite advances in diagnosis and treatment, the overall prognosis for patients with KRAS-driven lung cancer remains poor, underscoring the urgent need for a deeper understanding of the underlying molecular mechanisms. The gene discussed is KRAS; the disease is lung carcinoma.